Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter Learning 500 Chinese characters in 30 days is possible. Abstract • About

Breast Cancer

Free Subscription 16.02.2026 3 AJR Am J Roentgenol 1 Am J Clin Oncol 1 Ann Surg 14 Ann Surg Oncol 12 BMC Cancer 6 Breast Cancer 1 Breast Cancer Res 7 Breast Cancer Res Treat 4 Cancer 1 Cancer Cell 1 Cancer Epidemiol Biomarkers Prev 3 Cancer Res 12 Clin Breast Cancer 3 Clin Cancer Res 1 Curr Treat Options Oncol 1 Eur J Cancer 4 Eur J Surg Oncol 2 Histopathology 1 Int J Cancer 1 Int J Radiat Oncol Biol Phys 1 J Clin Oncol 2 J Natl Cancer Inst 1 J Surg Oncol 1 Nature 7 NPJ Breast Cancer 1 Oncogene 5 PLoS One

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

AJR Am J Roentgenol

1. YOON JH, Lee HS, Chung J, Kim HJ, et al
   Commercially Available Artificial Intelligence Score on Preoperative Mammography for Prediction of Future Breast Cancer After DCIS Treatment.
   AJR Am J Roentgenol. 2026 Feb 11. doi: 10.2214/AJR.25.34364.
   PubMed         Abstract available
   
   
2. CHIKARMANE SA, Thimm E, Plaxco JS, Chung S, et al
   Remote Diagnostic Breast Imaging: An Implementation Guide.
   AJR Am J Roentgenol. 2025 Oct 8. doi: 10.2214/AJR.25.33537.
   PubMed         Abstract available
   
   
3. SHAHRVINI T, Wood EJ, Joines MM, Nguyen H, et al
   Artificial Intelligence Versus Radiologist False-Positives on Digital Breast Tomosynthesis Examinations in a Population-Based Screening Program.
   AJR Am J Roentgenol. 2026;226:e2533412.
   PubMed         Abstract available
   
   

   
   Am J Clin Oncol

4. UCAR GC, Kapucu S, Donmez AA, Ozdemir O, et al
   Barriers to Adherence After a Self-Management Lymphedema Education Program Among Women With Breast Cancer-Related Lymphedema: A Qualitative Study.
   Am J Clin Oncol. 2026 Feb 12. doi: 10.1097/COC.0000000000001302.
   PubMed         Abstract available
   
   

   
   Ann Surg

5. FANNING JE, Tsai LL, Amore MA, Crescenzi R, et al
   Bringing to Light the Invisible Lymphatic Anatomy of the Upper Extremity: Report From the 2024 Harvard Radcliffe Institute Accelerator Workshop.
   Ann Surg. 2026;283:410-417.
   PubMed         Abstract available
   
   

   
   Ann Surg Oncol

6. WEISS A, Jin Q, Tayob N, Wrabel E, et al
   Axillary Management and Outcomes After Neoadjuvant Endocrine Therapy in the Randomized PELOPS Trial.
   Ann Surg Oncol. 2026;33:2275-2283.
   PubMed         Abstract available
   
   
7. SHERN TP, Holt LR, Chamberlain V, Gadd MA, et al
   Sentinel Lymph Node Biopsy for Prophylactic Mastectomy: Necessary Precaution or Unnecessary Procedure?
   Ann Surg Oncol. 2026;33:2316-2323.
   PubMed         Abstract available
   
   
8. ELAM M, Hillas J, Moyal-Smith R, Padamsee TJ, et al
   ASO Visual Abstract: Bridging Operative Standards to Clinical Practice: A Case Comparison of Synoptic Operative Report Implementation in Breast Cancer Surgery.
   Ann Surg Oncol. 2026 Feb 7. doi: 10.1245/s10434-026-19190.
   PubMed        
   
   
9. HOLMES DR
   ASO Author Reflections: Breast Cancer Cryoablation-A Targeted, Patient-Centered Approach Surgeons Should Embrace.
   Ann Surg Oncol. 2026 Feb 9. doi: 10.1245/s10434-026-19144.
   PubMed        
   
   
10. MASANAM MK, Bellon JR, Leone JP, Mittendorf EA, et al
    ASO Visual Abstract: Breast-Conserving Therapy for Multiple Ipsilateral Breast Cancer After Neoadjuvant Systemic Therapy.
    Ann Surg Oncol. 2026 Feb 9. doi: 10.1245/s10434-026-19163.
    PubMed        
    
    
11. WANG J, Chen J, Amburn T, Wagner BD, et al
    Axillary Lymph Node Dissection Through a Separate Incision Does Not Increase Rates of Breast Cancer-Related Lymphedema.
    Ann Surg Oncol. 2026 Feb 10. doi: 10.1245/s10434-026-19215.
    PubMed         Abstract available
    
    
12. PAN Y, Duan C, Du J, Zhang J, et al
    St. Gallen International Breast Cancer Consensus-Based Clinical Decision Validation: Concordance Assessment Between Deep Large Language Model Outputs and Global Expert Panel Recommendations.
    Ann Surg Oncol. 2026 Feb 10. doi: 10.1245/s10434-026-19176.
    PubMed         Abstract available
    
    
13. KO G, Cil TD
    ASO Author Reflections: Patterns of Breast Cancer Management and Surgical Wait Times During the COVID-19 Pandemic.
    Ann Surg Oncol. 2026 Feb 12. doi: 10.1245/s10434-026-19206.
    PubMed        
    
    
14. LEVINE A, Terrian L, Bishay D, Lawrence K, et al
    Reassessing the Role of Regular Physical Examination in Post-treatment Breast Cancer Surveillance.
    Ann Surg Oncol. 2026 Feb 12. doi: 10.1245/s10434-026-19227.
    PubMed         Abstract available
    
    
15. JIANG X, Huang Z, Wang X, Long J, et al
    Predictors of Pathological Complete Response to Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer: Development and Validation of a Clinical-Inflammatory Nomogram.
    Ann Surg Oncol. 2026 Feb 14. doi: 10.1245/s10434-026-19178.
    PubMed         Abstract available
    
    
16. WEISS A, Revette A, Nava-Coulter B, Mittendorf EA, et al
    Surgeon Perspectives on Axillary Management Following Neoadjuvant Endocrine Therapy: Results from a Qualitative Substudy of the PELOPS Trial.
    Ann Surg Oncol. 2026;33:2267-2274.
    PubMed         Abstract available
    
    
17. HARRIS N, Aiello P, Detz D, Hanssen D, et al
    Postoperative Impact of Closed Incision Negative Pressure Therapy Following Oncoplastic Breast Surgery.
    Ann Surg Oncol. 2026;33:2013-2018.
    PubMed         Abstract available
    
    
18. KIM CW, Yoo TK, Kim J, Chung IY, et al
    Postoperative Outcomes of Single-Port Robot-Assisted Versus Conventional Nipple-Sparing Mastectomy with Immediate Reconstruction.
    Ann Surg Oncol. 2026;33:2246-2254.
    PubMed         Abstract available
    
    
19. SHAMMAS RL, Wang J, Boe LA, Levy J, et al
    Radiation and Reconstructive Failure: Long-Term Outcomes in Two-Stage Flap Versus Implant Breast Reconstruction.
    Ann Surg Oncol. 2026;33:1981-1989.
    PubMed         Abstract available
    
    

    
    BMC Cancer

20. CONTRERAS-SANCHEZ SE, Doubova SV, Grajales-Alvarez R, Villalobos-Valencia R, et al
    Effectiveness of a digital health intervention on the supportive care needs and quality of life in Mexican patients with breast cancer: a randomized clinical trial.
    BMC Cancer. 2026 Feb 16. doi: 10.1186/s12885-026-15724.
    PubMed        
    
    
21. ZHANG L, Sun F, Wang X, Zhao W, et al
    Efficacy and safety of treatments in HR+/HER2- advanced breast cancer after CDK4/6 inhibitor progression: a network meta-analysis and scoping review.
    BMC Cancer. 2026 Feb 7. doi: 10.1186/s12885-026-15632.
    PubMed        
    
    
22. OZTURK HA, Koc M, Okyay RA, Ozturk DD, et al
    Cardioprotective effects of dapagliflozin against doxorubicin-induced cardiotoxicity in breast cancer patients with type 2 diabetes: a prospective study.
    BMC Cancer. 2026 Feb 7. doi: 10.1186/s12885-026-15696.
    PubMed         Abstract available
    
    
23. ADAMSON B, van Boemmel-Wegmann S, Horne E, Soares S, et al
    Real-world evidence from Germany: representativeness analysis and mortality endpoint validation in electronic health record-derived oncology cohorts.
    BMC Cancer. 2026;26:202.
    PubMed         Abstract available
    
    
24. LIAO H, Li H, Qu Y, Tang L, et al
    IL-8 positive cancer-associated fibroblasts drive breast cancer progression and immune evasion: insights from GWAS and single-cell transcriptomics.
    BMC Cancer. 2026 Feb 16. doi: 10.1186/s12885-026-15716.
    PubMed        
    
    
25. AROMAA-HAYHA A, Auvinen P, Malila N, Kataja V, et al
    Nonadherence to changing guidelines in early breast cancer over two decades.
    BMC Cancer. 2026 Feb 16. doi: 10.1186/s12885-026-15731.
    PubMed        
    
    
26. EL-KHAZRAGY N, Alsolami A, Aref AM, Hassan MNM, et al
    MiR-200c restoration inhibits FOXP3 and metastatic spread in breast cancer: evidence from in vitro and in vivo models.
    BMC Cancer. 2026 Feb 14. doi: 10.1186/s12885-026-15574.
    PubMed         Abstract available
    
    
27. ZHANG J, Dai C, Wang S, Chen Y, et al
    An evaluation model of chemotherapy efficacy in breast cancer based on combined serum CA15-3, CEA, and CYFRA 21 - 1.
    BMC Cancer. 2026 Feb 14. doi: 10.1186/s12885-026-15687.
    PubMed         Abstract available
    
    
28. OKTEN IN, Baydas T, Koca S, Baltaci MF, et al
    Breast cancer surgery in the era of genetic uncertainty: real-world outcomes in BRCA1/2 pathogenic variants and variants of uncertain significance.
    BMC Cancer. 2026 Feb 13. doi: 10.1186/s12885-026-15721.
    PubMed         Abstract available
    
    
29. GAO Y, Gong J, Yang Y, Luo Y, et al
    Stratified prediction of HER2 status in breast cancer by integrating intratumoral and peritumoral radiomics from DCE-MRI.
    BMC Cancer. 2026 Feb 13. doi: 10.1186/s12885-026-15688.
    PubMed        
    
    
30. KUBECZKO M, Polakiewicz-Gilowska A, Swiderska K, Mianowska-Malec M, et al
    Deciphering the role of Ki67: prognostic insights in advanced breast cancer therapy with Cyclin-dependent kinase 4/6 inhibitors.
    BMC Cancer. 2026 Feb 13. doi: 10.1186/s12885-026-15594.
    PubMed        
    
    
31. MAYBERRY SA, Hsu PC, Lin HY, Rogers LJ, et al
    Association of DNA methyltransferase polymorphisms with breast cancer: a nested case?control study of the Arkansas Rural Community Health study.
    BMC Cancer. 2026 Feb 10. doi: 10.1186/s12885-026-15695.
    PubMed        
    
    

    
    Breast Cancer

32. KOIZUMI K, Igarashi A, Gouldson M, Bilthare S, et al
    Cost-effectiveness analysis of the Oncotype DX Breast Recurrence Score((R)) test among node-negative early breast cancer patients in Japan.
    Breast Cancer. 2026 Feb 15. doi: 10.1007/s12282-026-01834.
    PubMed        
    
    
33. GAO Y, Chen L, Yao F, Wang J, et al
    FGFR4 and HER2 co-expression is associated with the proinflammatory tumor microenvironment in HR + breast cancer.
    Breast Cancer. 2026 Feb 11. doi: 10.1007/s12282-026-01833.
    PubMed         Abstract available
    
    
34. MASUDA H, Nagai SE, Hattori M, Yoshinami T, et al
    Real-world outcomes of palbociclib plus endocrine therapy in elderly patients with HR+/HER2- advanced breast cancer in Japan: a subgroup analysis of the P-BRIDGE study by age group.
    Breast Cancer. 2026 Feb 11. doi: 10.1007/s12282-025-01812.
    PubMed        
    
    
35. MANFUKU M, Imai R, Yono S, Kanamori H, et al
    Presenteeism in working-age breast cancer survivors 1-5 years after surgery: relative contributions of treatment-related symptoms and modifiable factors.
    Breast Cancer. 2026 Feb 9. doi: 10.1007/s12282-026-01835.
    PubMed         Abstract available
    
    
36. NISHIMURA R, Ueda Y, Kiyohara H, Funagayama M, et al
    An investigation to identify the factors for negative sentinel lymph node metastasis in early breast cancer cases.
    Breast Cancer. 2026 Feb 8. doi: 10.1007/s12282-026-01832.
    PubMed        
    
    
37. OTANI Y, Tanaka A, Rogachevskaya A, Ohtsu A, et al
    tRNA modification genes are associated with genomic instability, proliferative programs, and poor prognosis in breast cancer.
    Breast Cancer. 2026 Feb 7. doi: 10.1007/s12282-026-01830.
    PubMed        
    
    

    
    Breast Cancer Res

38. ZHAI Z, Wu J, Wei Y, Song P, et al
    O-GlcNAcylation regulates the DNA damage repair function of MND1 in breast cancer.
    Breast Cancer Res. 2026 Feb 10. doi: 10.1186/s13058-026-02233.
    PubMed        
    
    

    
    Breast Cancer Res Treat

39. WANG J, Bayard S, Assel M, Kim M, et al
    Remote symptom monitoring with clinical alerts following lumpectomy: do alerts predict 30-day re-operation or re-admission rates?
    Breast Cancer Res Treat. 2026;216:9.
    PubMed         Abstract available
    
    
40. BHARANI AN, Prateeksha A, Samanvay HP
    Letter to editor on the article by K.?H. Yoon et al., titled Impact of obesity on breast cancer recurrence by menopausal status and subtype.
    Breast Cancer Res Treat. 2026;216:7.
    PubMed        
    
    
41. BROWN NL, Howell SJ, Papantoniou D, Eriksson O, et al
    Prognostic performance of thymidine kinase 1 activity in patients with hormone receptor-positive and HER2-negative metastatic breast cancer treated with CDK4/6 and aromatase inhibitors.
    Breast Cancer Res Treat. 2026;216:6.
    PubMed         Abstract available
    
    
42. KLUGMAN MF, Aboumrad M, Chen R, Marshall CH, et al
    Defining prognostic subgroups and treatment outcomes in estrogen receptor low-positive de novo metastatic breast cancer.
    Breast Cancer Res Treat. 2026;216:5.
    PubMed         Abstract available
    
    
43. MARTIN E, Chichua M, Chiodi CK, Zyumbileva P, et al
    ATTITUDE - Addressing attrition in longitudinal cancer cohorts: an in-depth qualitative analysis of experiences and perspectives on participation in longitudinal studies among breast cancer survivors.
    Breast Cancer Res Treat. 2026;216:4.
    PubMed         Abstract available
    
    
44. KAJA E, Grupinska J, Budzyn M, Ciomborowska-Basheer J, et al
    Disease- and chemotherapy-associated salivary microbiome changes in breast cancer patients.
    Breast Cancer Res Treat. 2026;216:2.
    PubMed         Abstract available
    
    
45. PARSONS K, Yin H, Yu OHY, Khosrow-Khavar F, et al
    The association between pre-existing type 2 diabetes on cancer-related and all-cause mortality among women with breast cancer.
    Breast Cancer Res Treat. 2026;216:3.
    PubMed         Abstract available
    
    

    
    Cancer

46. LIMA SM, Palermo TM, Tian L, Lee FF, et al
    The effect of time on associations between historical redlining and breast cancer survival.
    Cancer. 2026;132:e70230.
    PubMed         Abstract available
    
    
47. SCHUMACHER JR, Hanlon BM, Zahrieh D, Rathouz PJ, et al
    Impact of a web-based breast cancer surgery decision aid on knowledge and perceptions of feeling informed in clinics that care for socioeconomically disadvantaged patients: An Alliance Clinical Trial (A231701CD).
    Cancer. 2026;132:e70314.
    PubMed         Abstract available
    
    
48. NIERENBERG TC, Thomas SM, Reason EH, Modell Parrish KJ, et al
    Breast cancer staging for patients with "low-risk" disease: Are they all the same?
    Cancer. 2026;132:e70305.
    PubMed         Abstract available
    
    
49. ZHANG L, Zheng A, Cao Y, Zhang T, et al
    Sentinel lymph node biopsy using dye alone in patients with initial clinical N1 breast cancer receiving neoadjuvant therapy: A multicenter diagnostic trial (Northern Breast Cancer Collaboration Group NBCG-002).
    Cancer. 2026;132:e70298.
    PubMed         Abstract available
    
    

    
    Cancer Cell

50. GOMEZ MARTI JL, Michaels E, Nasrazadani A, Wander SA, et al
    Enhancing therapeutic outcomes with artificial intelligence for HR-positive, HER2-negative metastatic breast cancer.
    Cancer Cell. 2026;44:254-256.
    PubMed         Abstract available
    
    

    
    Cancer Epidemiol Biomarkers Prev

51. NGUYEN THT, Jeon S, Yoon J, Park B, et al
    The Role of Adiposity and Lipid Biomarkers in Postmenopausal Breast Cancer Risk: A Causal Mediation Analysis Based on a Nationwide Cohort Study.
    Cancer Epidemiol Biomarkers Prev. 2026 Feb 9. doi: 10.1158/1055-9965.EPI-25-1504
    PubMed         Abstract available
    
    

    
    Cancer Res

52. SINGHAL S, Li C, Aukerman A, Carriere M, et al
    Topology-Based Biomarkers Accurately Predict Breast Cancer Outcome and Survival.
    Cancer Res. 2026 Feb 9. doi: 10.1158/0008-5472.CAN-25-1216.
    PubMed         Abstract available
    
    
53. ORTEGA-ALVAREZ D, Tebar-Garcia D, Casado-Pelaez M, Olivares-Osuna D, et al
    Discovery and Evaluation of Biomarkers for Triple-Negative Breast Cancer Subtypes Uncovers Patient Stratification and Targeted Therapeutic Strategies.
    Cancer Res. 2026 Feb 11. doi: 10.1158/0008-5472.CAN-24-2758.
    PubMed         Abstract available
    
    
54. LUO Z, Li K, Yu Y, Liu Y, et al
    LDHB Deficiency in Fibroblasts Induces Lactate-Mediated Inflammatory Reprogramming that Promotes Breast Cancer Metastasis.
    Cancer Res. 2026 Feb 13. doi: 10.1158/0008-5472.CAN-25-2792.
    PubMed         Abstract available
    
    

    
    Clin Breast Cancer

55. HE Z, Li X, He J, Huang P, et al
    Noninvasive Prediction of Axillary Sentinel Lymph Node Metastasis via Contrast-Enhanced Ultrasound to Guide Omission of SLNB in Breast Cancer.
    Clin Breast Cancer. 2026;26:74-83.
    PubMed         Abstract available
    
    
56. SHEELA IJ, Jeya Ranchani AA, Murali A, Premkumar H, et al
    Breast Cancer Vaccines: A Review of Emerging Opportunities and Persistent Challenges.
    Clin Breast Cancer. 2026;26:54-64.
    PubMed         Abstract available
    
    
57. VERGHIS NM, Senol K, Imoto S, Ordonez C, et al
    Contralateral Risk Reduction Mastectomy in Patients With Unilateral Breast Cancer Scheduled for Mastectomy: A Multidisciplinary Survey; Physicians' Perspective.
    Clin Breast Cancer. 2026;26:44-53.
    PubMed         Abstract available
    
    
58. XU P, Zhang X, Lu L, Chen X, et al
    Digital Health Management via IKAP Theory Improves Upper Limb Function and Psychological Adaptation in Postmastectomy Patients: A Randomized Controlled Trial.
    Clin Breast Cancer. 2026;26:161-169.
    PubMed         Abstract available
    
    
59. SCHNELL L, Orawa H, Wurschi GW, Pietschmann K, et al
    An Individual Patient Data Meta-Analysis on the Characteristics, Treatments, and Outcomes of the Patients With Neuroendocrine Neoplasm of the Breast Reported in Literature Until August 2024.
    Clin Breast Cancer. 2026;26:146-160.
    PubMed         Abstract available
    
    
60. DURGEKAR TD, Ghosh S, Savitha BA, Shrivastava P, et al
    CanAssist Breast Provides Additional Insightful Prognostic Information in Retrospective, Pooled Secondary Analysis in Clinically Low/ High-Risk Patients With HR+/HER2- EBC.
    Clin Breast Cancer. 2026;26:216-227.
    PubMed         Abstract available
    
    
61. WARDEN C, Steed K, Hotsinpiller W, Pogue J, et al
    CBCT-Guided Online Adaptive Radiation Therapy for Accelerated Partial Breast Irradiation: A Single-Institution Experience.
    Clin Breast Cancer. 2026;26:170-180.
    PubMed         Abstract available
    
    
62. COLCIAGO RR, Giandini C, Cavallo A, Carnevale MG, et al
    Event-Free Survival After Stereotactic Body Radiation Therapy for Oligoprogressive Metastatic Breast Cancer.
    Clin Breast Cancer. 2026;26:27-38.
    PubMed         Abstract available
    
    
63. GOSEIN M, Khoo E, Yong-Hing C, Sam J, et al
    Surveillance Contrast-Enhanced Mammography in Patients With Dense Breasts and a Personal History of Breast Cancer.
    Clin Breast Cancer. 2026;26:17-26.
    PubMed         Abstract available
    
    
64. HARRIS E, Daroui P, Gonzalez V, Ye JC, et al
    American Radium Society Appropriate Use Criteria Report on Radiation in the Management of Ductal Carcinoma in Situ (DCIS) of the Breast.
    Clin Breast Cancer. 2026;26:105-112.
    PubMed         Abstract available
    
    
65. KNOEDLER S, Schaschinger T, Klimitz FJ, Diatta F, et al
    Minutes that Matter? The Significance of Operative Time in Immediate Unilateral and Bilateral Free Flap Breast Reconstruction.
    Clin Breast Cancer. 2026;26:304-312.
    PubMed         Abstract available
    
    
66. KIM DK, Huang H, Kim JA, Rohde CH, et al
    Patient-Provider Relationships Influence Reception of Postmastectomy Breast Reconstruction: An Analysis of the All of Us Research Program.
    Clin Breast Cancer. 2026;26:287-295.
    PubMed         Abstract available
    
    

    
    Clin Cancer Res

67. NIRAVATH P, Uzair I, Sun K, Mai H, et al
    A phase II study of docetaxel and pembrolizumab plus Interleukin-12 gene therapy in non-metastatic, anthracycline-refractory triple negative breast cancer (INTEGRAL).
    Clin Cancer Res. 2026 Feb 9. doi: 10.1158/1078-0432.CCR-25-2649.
    PubMed         Abstract available
    
    
68. GRIGUOLO G, Bottosso M, Landa G, Bonomi G, et al
    Proactive brain screening using contrast-enhanced brain CT scans in HER2+ metastatic breast cancer.
    Clin Cancer Res. 2026 Feb 9. doi: 10.1158/1078-0432.CCR-25-3557.
    PubMed         Abstract available
    
    
69. ROSESHTER T, Klemantovich A, Lafleur J, Lan C, et al
    Clinical Validation of Digital PCR-based ctDNA detection for risk stratification in residual triple negative breast cancer: TRICIA trial results.
    Clin Cancer Res. 2026 Feb 9. doi: 10.1158/1078-0432.CCR-25-2234.
    PubMed         Abstract available
    
    

    
    Curr Treat Options Oncol

70. PENG L, Wang X, Zhang C, Liu T, et al
    Understanding, Recognizing, and Managing Cancer-Related Fatigue Associated with Breast Cancer.
    Curr Treat Options Oncol. 2026;27:9.
    PubMed        
    
    

    
    Eur J Cancer

71. ARISTEI C, Tomatis M, Ponti A, Marotti L, et al
    Impact of whole breast irradiation, endocrine therapy or their combination on outcomes of early-stage, luminal A-like, low-risk, breast cancer patients aged 65 years or over: Insights from the EUSOMA database.
    Eur J Cancer. 2026;236:116259.
    PubMed         Abstract available
    
    

    
    Eur J Surg Oncol

72. ZHANG C, Lodi M
    Immediate and delayed lymphatic reconstruction of breast-cancer related lymphedema: A systematic review and network meta-analysis.
    Eur J Surg Oncol. 2026;52:111394.
    PubMed         Abstract available
    
    
73. YU X, Zhang C, Fu M
    The European burden of breast cancer in 2022.
    Eur J Surg Oncol. 2026;52:111420.
    PubMed         Abstract available
    
    
74. LIAO N, Liu N, Zhang G, Ren C, et al
    Ultrasound-guided, indocyanine green-directed robot-assisted surgery for breast cancer with negative margins: A single center study.
    Eur J Surg Oncol. 2026;52:111445.
    PubMed         Abstract available
    
    
75. VERHEUL EM, Karsten MM, Gebert P, Doppelbauer L, et al
    Development and validation of prediction models for health-related quality of life outcomes after breast cancer surgery and reconstruction.
    Eur J Surg Oncol. 2026;52:111466.
    PubMed         Abstract available
    
    

    
    Histopathology

76. NAKAMURA H, Kukita Y, Kittaka N, Kusama H, et al
    Apocrine carcinoma of the breast: distinctive metabolic reprogramming and high-frequency PIK3CA mutations revealed by molecular and immunohistochemical analysis.
    Histopathology. 2026;88:790-809.
    PubMed         Abstract available
    
    
77. RAKHA EA, Tan PH, Raymond WA
    The spectrum of breast in situ papillary carcinomas with invasion and invasive breast carcinomas with papillary features: an overview of histological subtypes and diagnostic challenges.
    Histopathology. 2026;88:747-768.
    PubMed         Abstract available
    
    

    
    Int J Cancer

78. GKEKOS L, Gunnarsdottir KA, Humphreys K, Fredriksson I, et al
    Age-specific breast cancer incidence by subtype, TNM stage and screening status in Sweden 2008-2019 estimated with multiple imputation.
    Int J Cancer. 2026 Feb 12. doi: 10.1002/ijc.70355.
    PubMed         Abstract available
    
    

    
    Int J Radiat Oncol Biol Phys

79. KARP JM, Schnabel F, Bs JX, Oh C, et al
    Initiation and Completion of Endocrine Therapy in Older Women with Early-Stage Breast Cancer.
    Int J Radiat Oncol Biol Phys. 2026 Feb 12:S0360-3016(26)00375.
    PubMed         Abstract available
    
    

    
    J Clin Oncol

80. TARANTINO P
    Erratum: Rise and Fall of Neoadjuvant Carboplatin for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.
    J Clin Oncol. 2026 Feb 9:JCO2600219. doi: 10.1200/JCO-26-00219.
    PubMed        
    
    

    
    J Natl Cancer Inst

81. TUNG N, Hollis RL, Viale G, Tweed C, et al
    Questions and answers on PARP inhibitor use in somatic BRCA-mutated breast cancers.
    J Natl Cancer Inst. 2026;118:205-213.
    PubMed         Abstract available
    
    
82. RICHMAN IB, Lindsay ME, Long JB, Epstein E, et al
    Diagnostic yield of surveillance mammography among older women.
    J Natl Cancer Inst. 2026;118:223-230.
    PubMed         Abstract available
    
    

    
    J Surg Oncol

83. CRISTOFALO MM, Maesaka JY, Pereira DA, Nobrega GB, et al
    Neoadjuvant Chemotherapy in Triple Negative Breast Cancer: A Systematic Review of Breast and Node Pathologic Response.
    J Surg Oncol. 2026 Feb 15. doi: 10.1002/jso.70213.
    PubMed         Abstract available
    
    

    
    Nature

84. SOMER J, Mannor S, Alon U
    Temporal tissue dynamics from a spatial snapshot.
    Nature. 2026;650:490-499.
    PubMed         Abstract available
    
    

    
    NPJ Breast Cancer

85. TASTSOGLOU S, Karagounis IV, Miliotis M, Nagandla H, et al
    Estrogen receptor beta target gene expression reveals novel repressive functions in aggressive breast cancer.
    NPJ Breast Cancer. 2026 Feb 7. doi: 10.1038/s41523-026-00905.
    PubMed         Abstract available
    
    
86. PASANISI J, Lamy C, Lecompte L, Vacher S, et al
    Constitutional BRCA1 Methylation is associated with high level of tumoral BRCA1 methylation and homologous recombination deficiency in triple-negative breast cancer.
    NPJ Breast Cancer. 2026 Feb 7. doi: 10.1038/s41523-026-00906.
    PubMed         Abstract available
    
    
87. SINGAREEKA RAGHAVENDRA A, Liu DD, Pasyar S, Damodaran S, et al
    Prevalence of HER2-low status and outcomes in early-stage HER2-negative breast cancer.
    NPJ Breast Cancer. 2026 Feb 9. doi: 10.1038/s41523-026-00901.
    PubMed         Abstract available
    
    
88. KUBECZKO M, Cobo S, Sanchez-Bayona R, Pycinski B, et al
    Validation of the HER2DX genomic test in first-line advanced HER2-positive breast cancer treated with trastuzumab, pertuzumab, and taxane.
    NPJ Breast Cancer. 2026 Feb 10. doi: 10.1038/s41523-026-00909.
    PubMed         Abstract available
    
    
89. ZIEGLER Y, Kumar S, Saeh CM, Plotner BN, et al
    JAK/STAT1-interferon-ISGylation networks in breast cancer resistance to inhibitors of FOXM1 and CDK4/6.
    NPJ Breast Cancer. 2026 Feb 12. doi: 10.1038/s41523-026-00911.
    PubMed         Abstract available
    
    
90. TARANTINO P, Cha J, Binboga Kurt B, Chu X, et al
    Androgen receptor expression and immune characteristics of HER2-low metastatic triple-negative breast cancer.
    NPJ Breast Cancer. 2026 Feb 13. doi: 10.1038/s41523-026-00913.
    PubMed         Abstract available
    
    
91. HSIEH CH, Hsu MY, Lin CF, Liu CC, et al
    Programmable local immunochemotherapy for triple-negative breast cancer via spatiotemporally controlled release of CpG oligodeoxynucleotides, gemcitabine, and paclitaxel.
    NPJ Breast Cancer. 2026 Feb 13. doi: 10.1038/s41523-026-00910.
    PubMed         Abstract available
    
    

    
    Oncogene

92. DIAO H, Chen J, Zhang Y, Hua H, et al
    BRD4 orchestrates the metabolic-epigenetic regulation of GM-CSF expression and secretion to drive PD-L1(+) macrophage-mediated immune evasion in triple-negative breast cancer.
    Oncogene. 2026 Feb 14. doi: 10.1038/s41388-026-03681.
    PubMed         Abstract available
    
    

    
    PLoS One

93. SANCHEZ-SALDANA L, Lozada-Urbano M, Sullcahuaman-Allende Y, Cotrina-Concha J, et al
    Anthropometric and biochemical nutritional indicators and survival in women with breast cancer: A retrospective cohort study.
    PLoS One. 2026;21:e0341500.
    PubMed         Abstract available
    
    
94. WANG Y, Feng L, He L, Liu N, et al
    Al18F-NOTA-FAPI-04 PET/CT for diagnosis of breast cancer and its correlation with pathological features: A single-center retrospective study.
    PLoS One. 2026;21:e0342769.
    PubMed         Abstract available
    
    
95. 
    Expression of Concern: Tumor Associated Macrophage x Cancer Cell Hybrids May Acquire Cancer Stem Cell Properties in Breast Cancer.
    PLoS One. 2026;21:e0342526.
    PubMed        
    
    
96. FATHIMATHUL RAJEENA PP, Yasir M, Ali MAS, Khan JA, et al
    Breast cancer inter-image dissimilarity by feature optimization: An application of novel flea optimization algorithm.
    PLoS One. 2026;21:e0341848.
    PubMed         Abstract available
    
    
97. ZHOU R, Yu X, Wang J
    High accuracy breast cancer classification with BIRADS and coclustering.
    PLoS One. 2026;21:e0340772.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum